The federal government said Sept. 23 that it will cover the cost for 60,000 doses of bebtelovimab, Eli Lilly’s COVID-19 antibody drug. The news comes about a month after the drugmaker started selling the treatment commercially for $2,000 per dose.
In the aftermath of the failed rollout of HealthCare.gov, the White House created the U.S. Digital Service. Charles Worthington’s job there was, as he put it, to “help the government be more awesome at delivering software.”
Less than a month after federal regulators authorized Moderna and Pfizer’s modified COVID-19 boosters for emergency use, the vaccine-makers are looking for the FDA’s OK on their pediatric version.
Pain Specialists of America, an interventional pain management group, has integrated the new Proclaim Plus spinal cord stimulation system with FlexBurst360 therapy for patients receiving neuromodulation therapy for chronic pain.
A chain of primary care clinics in Minneapolis is responding to the nation’s physician shortage with a unique model: staffing nurse practitioners only, Medscape reported Sept. 23.